Endostatin
Phase 2Completed 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Vestibular Schwannoma
Conditions
Vestibular Schwannoma, Neurofibromatosis Type 2
Trial Timeline
Jan 1, 2014 → Apr 1, 2016
NCT ID
NCT02104323About Endostatin
Endostatin is a phase 2 stage product being developed by Tiantan Bio for Vestibular Schwannoma. The current trial status is completed. This product is registered under clinical trial identifier NCT02104323. Target conditions include Vestibular Schwannoma, Neurofibromatosis Type 2.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02104323 | Phase 2 | Completed |
Competing Products
2 competing products in Vestibular Schwannoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab Prefilled Syringe + Placebo | Eli Lilly | Phase 2 | 52 |
| Nilotinib | Novartis | Phase 2 | 52 |